Aurora Cannabis (ACB) Hisse Özeti
Aurora Cannabis Inc. iştirakleri ile birlikte Kanada'da ve uluslararası alanda esrar ve esrar türevi ürünlerin üretimi, dağıtımı ve satışı ile ilgilenmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 5/6 |
| Gelecekteki Büyüme | 1/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 5/6 |
| Temettüler | 0/6 |
ACB Community Fair Values
Create NarrativeSee what 55 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Aurora Cannabis Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | CA$3.70 |
| 52 Haftanın En Yüksek Seviyesi | CA$9.33 |
| 52 Haftanın En Düşük Seviyesi | CA$3.59 |
| Beta | 1.35 |
| 1 Aylık Değişim | -10.41% |
| 3 Aylık Değişim | -26.59% |
| 1 Yıllık Değişim | -40.51% |
| 3 Yıllık Değişim | -44.78% |
| 5 Yıllık Değişim | -95.84% |
| Halka arzdan bu yana değişim | -93.15% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jul 07
ACB: Medical Focus And Rescheduling Tailwinds Will Drive Future Upside Potential
Aurora Cannabis’ updated analyst price target has moved from CA$10.00 to CA$8.00 as analysts factor in lower modeled profit margins, a higher discount rate, and more conservative revenue growth assumptions, despite viewing recent partial cannabis rescheduling efforts as extremely favorable for the sector. What is in the News for Aurora Cannabis Aurora Cannabis issued earnings guidance for 2027, outlining a plan to exit lower margin Canadian consumer and plant propagation businesses and concentrate resources on global medical cannabis, with a focus on markets such as Germany and Poland.
Anlatı Güncellemesi • Jun 23
ACB: Favorable Rescheduling Outlook Will Support Shift To Global Medical Focus
Analysts have revised their fair value estimate for Aurora Cannabis from CA$7.93 to CA$6.14, citing updated expectations for revenue growth, profit margins, and a higher future P/E multiple following recent research that views partial cannabis rescheduling as extremely favorable for the sector. What’s in the News for Aurora Cannabis Aurora Cannabis issued earnings guidance for 2027, outlining plans to exit lower margin Canadian consumer and plant propagation businesses and to concentrate resources on global medical cannabis, with a focus on what the company views as higher return opportunities.Recent updates
Anlatı Güncellemesi • Jul 07
ACB: Medical Focus And Rescheduling Tailwinds Will Drive Future Upside Potential
Aurora Cannabis’ updated analyst price target has moved from CA$10.00 to CA$8.00 as analysts factor in lower modeled profit margins, a higher discount rate, and more conservative revenue growth assumptions, despite viewing recent partial cannabis rescheduling efforts as extremely favorable for the sector. What is in the News for Aurora Cannabis Aurora Cannabis issued earnings guidance for 2027, outlining a plan to exit lower margin Canadian consumer and plant propagation businesses and concentrate resources on global medical cannabis, with a focus on markets such as Germany and Poland.Anlatı Güncellemesi • Jun 23
ACB: Favorable Rescheduling Outlook Will Support Shift To Global Medical Focus
Analysts have revised their fair value estimate for Aurora Cannabis from CA$7.93 to CA$6.14, citing updated expectations for revenue growth, profit margins, and a higher future P/E multiple following recent research that views partial cannabis rescheduling as extremely favorable for the sector. What’s in the News for Aurora Cannabis Aurora Cannabis issued earnings guidance for 2027, outlining plans to exit lower margin Canadian consumer and plant propagation businesses and to concentrate resources on global medical cannabis, with a focus on what the company views as higher return opportunities.
Anlatı Güncellemesi • Jun 05
ACB: Rescheduling Tailwinds And Medical Portfolio Expansion Will Shape Balanced Outlook
Analysts have adjusted their CA$ price target on Aurora Cannabis to reflect updated expectations for slightly improved revenue trends, a higher profit margin outlook, and a lower future P/E, supported in part by recent Street research that views partial cannabis rescheduling as extremely favorable for the sector. What's in the News Aurora Cannabis received Plant Breeders' Rights in Canada for two proprietary cultivars, Farm Gas and Driftwood Diesel, giving the company exclusive rights to grow, propagate, and sell products from these varieties across key medical markets.Anlatı Güncellemesi • May 09
ACB: Partial Rescheduling And Medical Portfolio Shifts Will Shape Balanced Outlook
Analysts have revised their Aurora Cannabis price target to CA$5.00 from CA$5.00, citing updated views on regulatory progress around partial cannabis rescheduling and its potential implications for the company’s risk profile and long term earnings power. Analyst Commentary Recent commentary highlights that partial cannabis rescheduling is viewed as extremely favorable for the sector, but bearish analysts remain cautious on how much of that potential is already reflected in Aurora Cannabis' valuation at the current CA$5.00 price target.Anlatı Güncellemesi • Apr 20
ACB: Reset P E Multiple And Equity Issuance Will Shape Balanced Outlook
Analysts have reduced their CA$ price target on Aurora Cannabis by CA$1. This change reflects updated views on profit margins, revenue trends, and a lower assumed future P/E multiple.Anlatı Güncellemesi • Apr 05
ACB: Revised P E Assumptions And Policy Signals Will Guide Balanced Outlook
Aurora Cannabis' consensus analyst price target has been reduced by CA$1 as analysts factor in updated views on revenue trends, margin expectations, and a lower assumed future P/E multiple. Analyst Commentary Recent research updates point to a more cautious tone around Aurora Cannabis, as analysts reassess what they are willing to pay for the stock in light of current revenue and margin expectations.Anlatı Güncellemesi • Mar 22
ACB: Policy Shifts And Margin Efficiency Will Shape Cautious Yet Balanced Outlook
Aurora Cannabis' consensus analyst price target has been reduced by CA$1, as analysts adjust their models to reflect slightly lower revenue expectations, modestly higher profit margins, and a marginally lower future P/E multiple. Analyst Commentary Recent Street research around Aurora Cannabis reflects a more cautious tone on valuation and execution, even where overall views remain constructive.Anlatı Güncellemesi • Mar 07
ACB: Policy Shifts And Margin Execution Will Shape Fairly Balanced Outlook
Narrative update overview The latest analyst update trims the Aurora Cannabis price target by CA$1. This reflects a shift to lower expected profit margins and a higher assumed future P/E multiple, while still leaning on prior bullish initiation as support for the longer-term story.Anlatı Güncellemesi • Feb 21
ACB: Policy Shift And Execution Uncertainty Will Shape Balanced Risk Profile
Aurora Cannabis: Narrative Update Analysts reduced their 12-month price target for Aurora Cannabis by CA$1. This reflects updated expectations that now assume slightly softer revenue growth, somewhat higher profit margins, and a lower future P/E multiple.Anlatı Güncellemesi • Feb 06
ACB: Mixed Policy And Execution Signals Will Shape Risk Profile Ahead
Analysts have trimmed their fair value target for Aurora Cannabis from C$6.00 to C$5.00. This reflects an updated view that factors in a higher discount rate, revised revenue growth assumptions, improved profit margin expectations, and a lower future P/E multiple after recent Street research, including the latest Canaccord price target cut and an earlier bullish initiation.Analiz Makalesi • Nov 07
Aurora Cannabis Inc. (TSE:ACB) Stocks Pounded By 28% But Not Lagging Industry On Growth Or Pricing
Aurora Cannabis Inc. ( TSE:ACB ) shares have retraced a considerable 28% in the last month, reversing a fair amount of...Analiz Makalesi • Oct 03
Is Aurora Cannabis (TSE:ACB) Weighed On By Its Debt Load?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • Aug 29
Aurora Cannabis Inc. (TSE:ACB) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Aurora Cannabis Inc. ( TSE:ACB ) shares have had a really impressive month, gaining 27% after a shaky period...Anlatı Güncellemesi • Aug 07
European And Australian Medical Cannabis Markets Will Unlock Enduring Potential
Despite substantial improvement in net profit margin and a sharply reduced future P/E ratio, the consensus analyst price target for Aurora Cannabis has decreased from CA$8.42 to CA$7.92. What's in the News Aurora Cannabis expects year-over-year net revenue growth in Q2 2026, primarily driven by an 8%–12% increase in its Global Medical Cannabis segment (Corporate Guidance – New/Confirmed, 2025-08-06).Analiz Makalesi • Jul 12
Aurora Cannabis Inc. (TSE:ACB) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Aurora Cannabis Inc. ( TSE:ACB ) shares have retraced a considerable 26% in the last month, reversing a fair amount of...Analiz Makalesi • Jun 26
Aurora Cannabis' (TSE:ACB) Earnings May Just Be The Starting Point
Investors were underwhelmed by the solid earnings posted by Aurora Cannabis Inc. ( TSE:ACB ) recently. We did some...Analiz Makalesi • May 23
After Leaping 29% Aurora Cannabis Inc. (TSE:ACB) Shares Are Not Flying Under The Radar
Those holding Aurora Cannabis Inc. ( TSE:ACB ) shares would be relieved that the share price has rebounded 29% in the...
Yeni Anlatı • Apr 26
EU GMP And TGA Expertise Will Expand Global Cannabis Reach
Strategic international expansion and regulatory changes in key markets could significantly boost future revenues and medical cannabis margins.Analiz Makalesi • Feb 04
Investors Give Aurora Cannabis Inc. (TSE:ACB) Shares A 26% Hiding
Unfortunately for some shareholders, the Aurora Cannabis Inc. ( TSE:ACB ) share price has dived 26% in the last thirty...Analiz Makalesi • Nov 22
Aurora Cannabis Inc.'s (TSE:ACB) Share Price Is Still Matching Investor Opinion Despite 29% Slump
Aurora Cannabis Inc. ( TSE:ACB ) shareholders that were waiting for something to happen have been dealt a blow with a...Analiz Makalesi • Aug 02
It's Unlikely That Aurora Cannabis Inc.'s (TSE:ACB) CEO Will See A Huge Pay Rise This Year
Key Insights Aurora Cannabis to hold its Annual General Meeting on 9th of August Salary of CA$773.6k is part of CEO...Analiz Makalesi • Jun 27
Aurora Cannabis Inc.'s (TSE:ACB) Share Price Is Still Matching Investor Opinion Despite 29% Slump
Aurora Cannabis Inc. ( TSE:ACB ) shares have retraced a considerable 29% in the last month, reversing a fair amount of...Analiz Makalesi • Feb 15
Why Aurora Cannabis' (TSE:ACB) Earnings Are Weaker Than They Seem
We didn't see Aurora Cannabis Inc.'s ( TSE:ACB ) stock surge when it reported robust earnings recently. We decided to...Hissedar Getirileri
| ACB | CA Pharmaceuticals | CA Pazar | |
|---|---|---|---|
| 7D | -4.1% | -1.4% | -0.2% |
| 1Y | -40.5% | 39.9% | 28.2% |
Getiri vs. Endüstri: ACB geçen yıl % 39.9 oranında getiri sağlayan Canadian Pharmaceuticals sektörünün gerisinde kaldı.
Getiri vs Piyasa: ACB geçen yıl % 28.2 oranında getiri sağlayan Canadian Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| ACB volatility | |
|---|---|
| ACB Average Weekly Movement | 7.2% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 9.5% |
| 10% most volatile stocks in CA Market | 16.6% |
| 10% least volatile stocks in CA Market | 3.6% |
İstikrarlı Hisse Senedi Fiyatı: ACB son 3 ayda Canadian piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: ACB 'nin haftalık oynaklığı ( 7% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2013 | 1,028 | Miguel Martin | www.auroramj.com |
Aurora Cannabis Inc. iştirakleriyle birlikte Kanada'da ve uluslararası alanda kenevir ve kenevir türevi ürünlerin üretimi, dağıtımı ve satışı ile uğraşmaktadır. Canadian Cannabis ve Plant Propagation olmak üzere iki segmentte faaliyet göstermektedir. Şirket tıbbi ve tüketici kenevir ürünleri sunmakta; çoğaltılmış sebze ve süs bitkileri tedarik etmekte ve kenevirden türetilmiş kannabidiol (CBD) ürünlerinin dağıtımını ve satışını yapmaktadır.
Aurora Cannabis Inc. Temel Bilgiler Özeti
| ACB temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | CA$225.47m |
| Kazançlar(TTM) | -CA$58.62m |
| Gelir(TTM) | CA$320.59m |
0.7x
P/S Oranı-3.9x
F/K OranıACB aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| ACB gelir tablosu (TTM) | |
|---|---|
| Gelir | CA$320.59m |
| Gelir Maliyeti | CA$183.94m |
| Brüt Kâr | CA$136.65m |
| Diğer Giderler | CA$195.27m |
| Kazançlar | -CA$58.62m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -0.95 |
| Brüt Marj | 42.62% |
| Net Kâr Marjı | -18.28% |
| Borç/Özkaynak Oranı | 0% |
ACB uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/17 05:44 |
| Gün Sonu Hisse Fiyatı | 2026/07/17 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2026/03/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Aurora Cannabis Inc. 15 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Etienne Ricard | BMO Capital Markets Equity Research |
| Heather Balsky | BofA Global Research |